Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

BRAIN Biotech

Main focus: Undisclosed

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: BRAIN-Engineered-Cas01 (BMC01) nuclease

Funding stage: Public (XETRA:BNN)

Location: Zwingenberg, Germany


BRAIN Biotech is a company focused on providing solutions for industrial biotechnology. The company's engagement in the gene-editing space comes through its development of novel non-Cas9 nucleases that are being validated for gene editing in bacteria, fungi, yeast as well as in mammalian cells. While the company does not have any disclosed therapeutic programmes, the novel Cas systems may provide a way to expand into the therapeutic space.


HashtagBRAIN Biotech AG

Company: BRAIN Biotech
Search CRISPR Medicine